- Ionis Pharmaceuticals (NASDAQ:IONS +0.9%) affiliate Akcea Therapeutics (NASDAQ:AKCA -0.1%) announces that it has received a letter-of-intent from the Pan-Canadian Pharmaceutical Alliance for reimbursement of Tegsedi (inotersen injection) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
- Negotiations with provinces, territories and federal agencies are next up.
- Health Canada approved the antisense oligonucleotide in October 2018.